Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Gw Pharmaceuticals Plc's Business Segments
Gw Pharmaceuticals Plc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 152
Regions Reported
-
Gw Pharmaceuticals Plc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Product100%
- Product and Service Other0%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 152 | 100% |
| Product and Service Other | $ 0 | 0% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Gw Pharmaceuticals Plc
GW Pharmaceuticals Plc is a British biopharmaceutical company that is focused on developing medicines derived from cannabis. The company was founded in 1998 and has its headquarters in Cambridge, United Kingdom. It is listed on the NASDAQ stock exchange under the ticker symbol "GWPH".
GW Pharmaceuticals has been a pioneer in the development of cannabis-based medicines. The company's primary focus is on the development and commercialization of medicines for the treatment of epilepsy, multiple sclerosis, and cancer pain. Its lead product, Epidiolex, is the first FDA-approved cannabis-based drug for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
GW Pharmaceuticals has also developed Sativex, a cannabis-based medicine for the treatment of spasticity in multiple sclerosis patients. Sativex is currently approved for use in over 25 countries, including the United Kingdom, Spain, Germany, Canada, and Australia.
The company has a strong research and development program, with a focus on developing medicines that have the potential to treat a wide range of medical conditions. GW Pharmaceuticals has a team of over 600 employees, including scientists, doctors, and other medical professionals, who are dedicated to developing innovative medicines.
In addition to its pharmaceutical activities, GW Pharmaceuticals also has a program focused on the development of plant-based therapies for the treatment of skin diseases such as eczema, psoriasis, and acne. The company has also developed a range of CBD-based products, including skin care products and drinks.
GW Pharmaceuticals has a diverse and robust pipeline of products in various stages of development, including additional cannabis-based medicines for the treatment of other conditions. The company is committed to the highest standards of scientific rigor and is focused on providing safe and effective treatments for patients with unmet medical needs.
GW Pharmaceuticals has been a pioneer in the development of cannabis-based medicines. The company's primary focus is on the development and commercialization of medicines for the treatment of epilepsy, multiple sclerosis, and cancer pain. Its lead product, Epidiolex, is the first FDA-approved cannabis-based drug for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
GW Pharmaceuticals has also developed Sativex, a cannabis-based medicine for the treatment of spasticity in multiple sclerosis patients. Sativex is currently approved for use in over 25 countries, including the United Kingdom, Spain, Germany, Canada, and Australia.
The company has a strong research and development program, with a focus on developing medicines that have the potential to treat a wide range of medical conditions. GW Pharmaceuticals has a team of over 600 employees, including scientists, doctors, and other medical professionals, who are dedicated to developing innovative medicines.
In addition to its pharmaceutical activities, GW Pharmaceuticals also has a program focused on the development of plant-based therapies for the treatment of skin diseases such as eczema, psoriasis, and acne. The company has also developed a range of CBD-based products, including skin care products and drinks.
GW Pharmaceuticals has a diverse and robust pipeline of products in various stages of development, including additional cannabis-based medicines for the treatment of other conditions. The company is committed to the highest standards of scientific rigor and is focused on providing safe and effective treatments for patients with unmet medical needs.
GW Pharmaceuticals Plc is a pioneering biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative prescription cannabinoid medicines. The company has a significant presence in the cannabis-derived medicine sector, leveraging the therapeutic properties of cannabinoids to address various medical conditions.
Segments
GW Pharmaceuticals operates through two primary segments, each focusing on distinct therapeutic applications of cannabinoid-based products:
1. Sativex: This segment features Sativex, an oromucosal spray that provides relief from spasticity symptoms associated with multiple sclerosis (MS). Sativex contains a balanced 1:1 formulation of THC (tetrahydrocannabinol) and CBD (cannabidiol), which are two of the most researched cannabinoids. The product is designed to be administered via the oral mucosa for rapid absorption. Sativex has gained regulatory approval and is marketed in over 15 countries globally, indicating its strong acceptance and the growing recognition of cannabinoid therapies for neurological conditions.
2. Epidiolex: The second segment focuses on Epidiolex, which is a groundbreaking prescription medicine approved for the treatment of seizures related to Lennox-Gastaut syndrome and Dravet syndrome, both of which are rare and severe forms of epilepsy. Epidiolex contains pure CBD and represents a significant milestone as the first FDA-approved drug derived entirely from cannabis. The availability of Epidiolex extends beyond the United States to markets in Europe and several other jurisdictions, illustrating its global impact on managing pediatric epilepsy.
Products and Services
GW Pharmaceuticals comprehensive portfolio of products and services highlights its commitment to advancing cannabinoid-based medicine and expanding treatment options for patients with severe medical conditions. Some key offerings include:
1. Epidiolex: The flagship product that addresses the pressing needs of patients suffering from treatment-resistant epilepsy, providing a clinically validated option that improves seizure control and overall quality of life.
2. Sativex: Approved for use in managing spasticity symptoms in MS patients, this product exemplifies the companys efforts to provide symptomatic relief for chronic conditions through cannabinoid therapies.
3. Cannabinoid-based Products: GW Pharmaceuticals is actively engaged in researching and developing a variety of new cannabinoid-based medications aimed at treating various conditions beyond epilepsy and MS. This includes investigating potential therapies for schizoaffective disorder, autism spectrum disorders, and glioma, among others. The company seeks to unlock the therapeutic potential of cannabinoids through ongoing clinical trials and collaborations.
4. Clinical Research Services: In alignment with its commitment to innovation, GW Pharmaceuticals offers clinical research services that facilitate the development and testing of new cannabinoid-based therapies. These services encompass study design, implementation, and data analysis, thereby supporting both internal projects and external collaborations.
5. Supply Services: The company also operates a supply services segment that provides high-quality cannabis extracts to researchers and other biopharmaceutical companies. This segment underscores GW Pharmaceuticals role as a key player in the cannabis research ecosystem, supplying vital resources necessary for advancing cannabinoid research.
Conclusion
GW Pharmaceuticals is at the forefront of the biopharmaceutical industry with its focus on cannabinoid medicines. Through its two primary segments—Sativex and Epidiolex—as well as its commitment to research and development, the company aims to reshape treatment paradigms for various medical conditions. By leveraging the therapeutic properties of cannabis, GW Pharmaceuticals is positioned as a leader in the evolving landscape of cannabinoid-based therapies, dedicated to improving patient outcomes and enhancing quality of life.
Segments
GW Pharmaceuticals operates through two primary segments, each focusing on distinct therapeutic applications of cannabinoid-based products:
1. Sativex: This segment features Sativex, an oromucosal spray that provides relief from spasticity symptoms associated with multiple sclerosis (MS). Sativex contains a balanced 1:1 formulation of THC (tetrahydrocannabinol) and CBD (cannabidiol), which are two of the most researched cannabinoids. The product is designed to be administered via the oral mucosa for rapid absorption. Sativex has gained regulatory approval and is marketed in over 15 countries globally, indicating its strong acceptance and the growing recognition of cannabinoid therapies for neurological conditions.
2. Epidiolex: The second segment focuses on Epidiolex, which is a groundbreaking prescription medicine approved for the treatment of seizures related to Lennox-Gastaut syndrome and Dravet syndrome, both of which are rare and severe forms of epilepsy. Epidiolex contains pure CBD and represents a significant milestone as the first FDA-approved drug derived entirely from cannabis. The availability of Epidiolex extends beyond the United States to markets in Europe and several other jurisdictions, illustrating its global impact on managing pediatric epilepsy.
Products and Services
GW Pharmaceuticals comprehensive portfolio of products and services highlights its commitment to advancing cannabinoid-based medicine and expanding treatment options for patients with severe medical conditions. Some key offerings include:
1. Epidiolex: The flagship product that addresses the pressing needs of patients suffering from treatment-resistant epilepsy, providing a clinically validated option that improves seizure control and overall quality of life.
2. Sativex: Approved for use in managing spasticity symptoms in MS patients, this product exemplifies the companys efforts to provide symptomatic relief for chronic conditions through cannabinoid therapies.
3. Cannabinoid-based Products: GW Pharmaceuticals is actively engaged in researching and developing a variety of new cannabinoid-based medications aimed at treating various conditions beyond epilepsy and MS. This includes investigating potential therapies for schizoaffective disorder, autism spectrum disorders, and glioma, among others. The company seeks to unlock the therapeutic potential of cannabinoids through ongoing clinical trials and collaborations.
4. Clinical Research Services: In alignment with its commitment to innovation, GW Pharmaceuticals offers clinical research services that facilitate the development and testing of new cannabinoid-based therapies. These services encompass study design, implementation, and data analysis, thereby supporting both internal projects and external collaborations.
5. Supply Services: The company also operates a supply services segment that provides high-quality cannabis extracts to researchers and other biopharmaceutical companies. This segment underscores GW Pharmaceuticals role as a key player in the cannabis research ecosystem, supplying vital resources necessary for advancing cannabinoid research.
Conclusion
GW Pharmaceuticals is at the forefront of the biopharmaceutical industry with its focus on cannabinoid medicines. Through its two primary segments—Sativex and Epidiolex—as well as its commitment to research and development, the company aims to reshape treatment paradigms for various medical conditions. By leveraging the therapeutic properties of cannabis, GW Pharmaceuticals is positioned as a leader in the evolving landscape of cannabinoid-based therapies, dedicated to improving patient outcomes and enhancing quality of life.